Despite counter campaigns by scientists and doctors, the FDA scientific advisory committee voted 18 to six in favour of approving the drug, with the condition that risk-management options were put in place. The committee members were concerned the drug had significant risks from side-effects, particularly if used off label or taken in combination with alcohol, and few benefits. The committee’s recommendation that the drug be approved therefore attracted widespread criticism that it allowed politics to trump clinical science.

Property	Description	Status
Approved Uses	Hypoactive Sexual Desire Disorder (HSDD) in women	Yes
Mechanism of Action	Serotonin receptor modulator	Partial agonist & antagonist
FDA Approval Year	2015
Common Brand Name	Addyi

Within hours of the FDA approval, Sprout Pharmaceuticals was acquired by Valeant for $US1 billion. Valeant set the price of Addyi at $US800 per month, leading to accusations of price gouging.

Commonly used brand name(s)

Flibanserin is approved for prescription only in the US; it is not available in Australia. US doctors must be certified before prescribing it, and dispensing pharmacists must also complete training. In the first month it was available, Addyi (the brand name of flibanserin) was prescribed just 227 times, compared with more than half a million for Viagra in its first month. Doctors had prescribed the drug fewer than 4,000 times as of February this year. In the US, a one-month supply of flibanserin (one 100mg tablet per day, taken at bed time) costs between $US200 to $US830, depending on insurance coverage and means of acquisition.

Dosage forms and strengths (USA)

That’s a lot of money for an extra sexually satisfying experience every two months. ∙ Sexual desire is regulated not only by the sex hormones testosterone and estrogen, but also by the neurotransmitters dopamine and norepinephrine, which enhance sexual interest and desire, and serotonin, which inhibits sexual interest and desire. ∙ Brain circuits that connect the prefrontal cortex (PFC) with limbic pleasure centers theoretically mediate motivation, interest, and desire. These circuits are hypothesized to be the sites of inefficient information processing associated with sexual disorders that are characterized by reduced interest and desire. Flibanserin theoretically improves sexual functioning by enhancing downstream release of dopamine and norepinephrine while reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire. Sales flagged as insurers refused to cover the drug. With its stock value plummeting, Valeant reportedly dismissed the drug’s entire sales team and said it planned to reintroduce the drug at a later date. The company may be waiting until the 18-month restriction on direct-to-consumer marketing is over.

Flibanserin's journey from failed antidepressant to HSDD treatment is unique.
Its development cost hundreds of millions of dollars over two decades.
The FDA initially rejected it in 2010 and 2013 due to safety/efficacy concerns.
Final 2015 approval came with the stringent REMS and boxed warning.
The approval process involved patient testimony and advocacy efforts.
It is classified as a multifunctional serotonin agonist and antagonist (MSAA).
Does not bind significantly to dopamine, norepinephrine, or histamine receptors.
Binding affinity is highest for serotonin 5-HT1A and 5-HT2A receptors.
Its metabolite, 6-hydroxy-flibanserin, is inactive.

A recent review of studies – including five published and three unpublished randomised clinical trials involving 5,914 women – concluded the overall quality of the evidence for both efficacy and safety outcomes was very low. The published studies reported more favourable outcomes than unpublished studies. The authors’ attempts to gain further information from study leaders and sponsors were not successful. Side-effects include dizziness (11.4% of users), drowsiness (11.2%), nausea (10.4%), fatigue (9.2%), insomnia (4.9%) and dry mouth (2.4%). The most serious problems – low blood pressure vardenafil oral and a resulting loss of consciousness – are amplified by concurrent alcohol use. Other serious adverse events were uncommon but flibanserin can’t be viewed as safe without further studies including a broader range of diverse women. The FDA approved flibanserin on condition it carry a black-box warning not to drink alcohol while taking the medication.

Product	Dosage	Quantity + Bonus	Price
Tadalista Super Active	20mg	60 + 8 Pills	230.32€ 219.35€
Viagra Oral Jelly	100mg	10 Sachets	46.36€ 44.15€
Cialis Original	20mg	48 + 4 Pills	224.69€ 213.99€
Kamagra Soft Tabs	100mg	60 + 4 Pills	180.59€ 171.99€
Viagra Professional	100mg	10 Pills	44.09€ 41.99€
Super Kamagra	160 mg	60 + 4 Pills	342.71€ 326.39€
Viagra Original	100mg	4 Pills	40.94€ 38.99€
Viagra Oral Jelly	100mg	90 + 8 Sachets	258.02€ 245.73€
Levitra Generic	60mg	360 + 10 Pills	906.69€ 863.51€
Kamagra Soft Tabs	100 mg	272 + 12 Pills	593.42€ 565.16€
Kamagra Oral Jelly	100mg	110 + 9 Sachets	334.87€ 318.92€

Adverse Effects

The authors’ attempts to gain further information from study leaders and sponsors were not successful. Side-effects include dizziness (11.4% of users), drowsiness (11.2%), nausea (10.4%), fatigue (9.2%), insomnia (4.9%) and dry mouth (2.4%). The most serious problems – low blood pressure vardenafil oral and a resulting loss of consciousness – are amplified by concurrent alcohol use. Other serious adverse events were uncommon but flibanserin can’t be viewed as safe without further studies including a broader range of diverse women. The FDA approved flibanserin on condition it carry a black-box warning not to drink alcohol while taking the medication.

Mechanism of Action

The manufacturer is also required to undertake three additional studies to examine the side-effects among women using alcohol with the drug. Strangely, the evidence about alcohol interactions with flibanserin presented to the FDA included data on 25 healthy volunteers, of whom only two were women. Side-effects are lessened if taken at night, but it has been reported about one out of every eight women will discontinue flibanserin because of adverse effects. A rigorous meta-analysis showed that, on average, flibanserin led to one-half an additional sexually satisfying event per month. This is a less optimistic finding than the (still underwhelming) one extra sexually satisfying event per month frequently quoted by reports. Side-effects are lessened if taken at night, but it has been reported about one out of every eight women will discontinue flibanserin because of adverse effects. A rigorous meta-analysis showed that, on average, flibanserin led to one-half an additional sexually satisfying event per month. This is a less optimistic finding than the (still underwhelming) one extra sexually satisfying event per month frequently quoted by reports. Flibanserin is approved for prescription only in the US; it is not available in Australia.

i have little to no sexual desire

Drug Interactions Table

Sales flagged as insurers refused to cover the drug. With its stock value plummeting, Valeant reportedly dismissed the drug’s entire sales team and said it planned to reintroduce the drug at a later date. The company may be waiting until the 18-month restriction on direct-to-consumer marketing is over. A recent review of studies – including five published and three unpublished randomised clinical trials involving 5,914 women – concluded the overall quality of the evidence for both efficacy and safety outcomes was very low. The published studies reported more favourable outcomes than unpublished studies. US doctors must be certified before prescribing it, and dispensing pharmacists must also complete training.

Flibanserin's development was rooted in attempts to find antidepressants with sexual side effects.
It was repurposed as a treatment for female sexual desire disorder.
The medication is available by prescription only.
It belongs to the class of serotonergic drugs affecting brain chemistry.
Women with liver disease should avoid taking flibanserin.
The medication is primarily metabolized in the liver via CYP3A4.
Flibanserin has been the subject of debates over its cost-benefit ratio.
It is not approved for use in men or non-binary individuals.
Clinical guidelines recommend using flibanserin only after other causes of low desire are addressed.

In the first month it was available, Addyi (the brand name of flibanserin) was prescribed just 227 times, compared with more than half a million for Viagra in its first month.

The Clinically Proven Treatment for Low Sexual Desire

Brain circuits of motivation and pleasure include frontostriatal pathways and neuronal projections involving the insula, amygdala, hypothalamus, and ventral striatum.Reference Georgiadis and Kringelbach 1 – Reference Pfaus 4 These brain areas hypothetically process rewarding stimuli, including sex, food, and drugs of abuse, along with other pleasurable stimuli, including the “runner’s high” of jogging, certain social experiences, relationships, achievements, aesthetics, and intellectual pursuits.Reference Georgiadis and Kringelbach 1 Recent research suggests that these same brain circuits are also involved when patients experience a lack of interest in and desire for sex.Reference Woodard, Nowak, Balon, Tancer and Diamond 5 , Reference Arnow, Millheiser and Garrett 6 Studies also indicate that a new therapeutic agent, flibanserin, improves interest in and desire for sex by hypothetically targeting these circuits and causing the release of dopamine and norepinephrine while also reducing the release of serotonin.Reference Stahl, Sommer and Allers 7 – Reference Aubert, Gustison and Gardner 11 Various psychiatric disorders affect reward processing and are associated with the loss of interest and desire to pursue pleasurable activities because they are no longer engaging or rewarding. Reward processing is one of the key symptom domains in the modern “dimensional approach” to psychiatric fildena super active 100 disordersReference Stahl 12 , Reference Insel, Cuthbert and Garvey 13 because abnormal reward processing hypothetically causes symptoms that can cut across a wide number of conditions, including major depressive disorder (MDD), schizophrenia, dementia, substance abuse, eating disorders, and sexual disorders.Reference Goto and Grace 14 Symptoms may include generalized anhedonia; reduced positive affect; and lack of energy, enthusiasm, happiness, and self-confidence.Reference Georgiadis and Kringelbach 1 , Reference Stahl 12 , Reference Insel, Cuthbert and Garvey 13 Reward processing is sometimes very specific, and various disorders can selectively disrupt interest in and desire for a particular type of reward. One example of this is a condition of reduced interest in and desire for sexual activity, called variously hypoactive sexual desire disorder (HSDD) or female sexual interest and arousal disorder (FSIAD). 15 Regardless of the disorder’s label, 15 , Reference Clayton, Goldfischer and Goldstein 16 if a woman suffers from prolonged loss of sexual desire that causes her distress and cannot be explained by problematic relationships, stressors, or medical conditions, then it is considered to be a disorder of reward processing for sex, and as such is hypothetically mediated by inefficient information processing in reward circuits.Reference Georgiadis and Kringelbach 1 – Reference Arnow, Millheiser and Garrett 6 Interest in and desire for sexual activity is the first phase of the human sexual response, followed by arousal, and then by orgasm (accompanied in men by ejaculation).Reference Georgiadis and Kringelbach 1 , Reference Pfaus 4 , Reference Stahl 17 , Reference Stahl 18 Disorders of orgasm and ejaculation have been recognized ever since the introduction of Prozac (fluoxetine) and the other selective serotonin reuptake inhibitors (SSRIs), which raise serotonin and commonly inhibit or delay orgasm/ejaculation.Reference Stahl 18 Disorders of arousal became well known with the introduction of Viagra (sildenafil citrate) and other nitric oxide synthase (NOS) inhibitors, which raise nitric oxide levels and enhance arousal, improving erections in men.Reference Stahl 18 Finally, disorders of interest in and desire for sex have also long been identified as a consequence of agents that enhance the release of serotonin (eg, SSRIs) or that block the release of dopamine (antipsychotics).Reference Stahl 3 , Reference Pfaus 4 , Reference Stahl 8 , Reference Stahl 18 However, until recently, primary disorders of interest in and desire for sex have not been well recognized.Reference Georgiadis and Kringelbach 1 – Reference Arnow, Millheiser and Garrett 6 Recent changes in diagnostic criteria for sexual disorders have arguably made it even more difficult to reach a primary diagnosis of loss of interest in and desire for sex. 15 Confusion exists because some diagnostic systems now merge disorders of interest and desire in women with disorders of arousal, while other diagnostic systems keep them separate.

Administration Notes

15 , Reference Clayton, Goldfischer and Goldstein 16 Fortunately, as often occurs when a new therapeutic emerges, things are becoming clearer. It now seems that the primary disorder of loss of sexual interest and desire (not a disorder of arousal or orgasm) can be recognized and treated successfully when it occurs in premenopausal women.Reference Stahl, Sommer and Allers 7 , Reference Stahl 18 – Reference Simon, Kingsberg, Shumel, Hanes, Garcia and Sand 23 A microcircuit is one way to describe what happens at the level of a synapse between 2 neurons (see boxes in Figures 1–3). This is classically where neurotransmitters regulate brain functions and where drugs act. For example, each phase of the human sexual response appears to be regulated by different neurotransmitters operating within different microcircuits.Reference Georgiadis and Kringelbach 1 , Reference Pfaus 4 , Reference Stahl 17 , Reference Stahl 18 Interest and desire—sometimes called libido—are positively regulated not only by synaptic (microcircuit) dopamine (Figure 1A), but also by other microcircuits where norepinephrine (Figure 2A), testosterone, and estrogen act. Libido is also negatively modulated by microcircuits where prolactin and serotonin act (Figure 3A).Reference Georgiadis and Kringelbach 1 , Reference Pfaus 4 , Reference Stahl 17 Disorders of sexual interest and desire are hypothetically linked therefore to relative deficiencies in microcircuit dopamine (compare the microcircuits in Figures 1A and 1B) and norepinephrine (compare the microcircuits in Figures 2A and 2B) and a relative excess in microcircuit serotonin (compare the microcircuits in Figures 3A and 3B).Reference Georgiadis and Kringelbach 1 , Reference Pfaus 4 , Reference Stahl 17 Furthermore, prefrontal cortex (PFC) circuits utilizing glutamate may be overly active when sexual desire is low.Reference Stahl 2 HSDD may therefore be considered a maladaptation of the brain that arises from excessive excitatory signaling from the PFC to subcortical reward-related structures, which in turn leads to aberrant processing of information from rewarding events in both limbic and cortical areas. Doctors had prescribed the drug fewer than 4,000 times as of February this year. In the US, a one-month supply of flibanserin (one 100mg tablet per day, taken at bed time) costs between $US200 to $US830, depending on insurance coverage and means of acquisition. That’s a lot of money for an extra sexually satisfying experience every two months. ∙ Sexual desire is regulated not only by the sex hormones testosterone and estrogen, but also by the neurotransmitters dopamine and norepinephrine, which enhance sexual interest and desire, and serotonin, which inhibits sexual interest and desire. ∙ Brain circuits that connect the prefrontal cortex (PFC) with limbic pleasure centers theoretically mediate motivation, interest, and desire.

Feature	Flibanserin	Bremelanotide	Vyleesi
Approved for HSDD	Yes	No	Yes
Administration Route	Oral	Injectable	Injectable
Usage Frequency	Daily	As needed	As needed
Main Side Effects	Dizziness, nausea	Nausea, flushing	Nausea, reactions at injection site

These circuits are hypothesized to be the sites of inefficient information processing associated with sexual disorders that are characterized by reduced interest and desire. Flibanserin theoretically improves sexual functioning by enhancing downstream release of dopamine and norepinephrine while reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire. Brain circuits of motivation and pleasure include frontostriatal pathways and neuronal projections involving the insula, amygdala, hypothalamus, and ventral striatum.Reference Georgiadis and Kringelbach 1 – Reference Pfaus 4 These brain areas hypothetically process rewarding stimuli, including sex, food, and drugs of abuse, along with other pleasurable stimuli, including the “runner’s high” of jogging, certain social experiences, relationships, achievements, aesthetics, and intellectual pursuits.Reference Georgiadis and Kringelbach 1 Recent research suggests that these same brain circuits are also involved when patients experience a lack of interest in and desire for sex.Reference Woodard, Nowak, Balon, Tancer and Diamond 5 , Reference Arnow, Millheiser and Garrett 6 Studies also indicate that a new therapeutic agent, flibanserin, improves interest in and desire for sex by hypothetically targeting these circuits and causing the release of dopamine and norepinephrine while also reducing the release of serotonin.Reference Stahl, Sommer and Allers 7 – Reference Aubert, Gustison and Gardner 11 Various psychiatric disorders affect reward processing and are associated with the loss of interest and desire to pursue pleasurable activities because they are no longer engaging or rewarding. Reward processing is one of the key symptom domains in the modern “dimensional approach” to psychiatric fildena super active 100 disordersReference Stahl 12 , Reference Insel, Cuthbert and Garvey 13 because abnormal reward processing hypothetically causes symptoms that can cut across a wide number of conditions, including major depressive disorder (MDD), schizophrenia, dementia, substance abuse, eating disorders, and sexual disorders.Reference Goto and Grace 14 Symptoms may include generalized anhedonia; reduced positive affect; and lack of energy, enthusiasm, happiness, and self-confidence.Reference Georgiadis and Kringelbach 1 , Reference Stahl 12 , Reference Insel, Cuthbert and Garvey 13 Reward processing is sometimes very specific, and various disorders can selectively disrupt interest in and desire for a particular type of reward. One example of this is a condition of reduced interest in and desire for sexual activity, called variously hypoactive sexual desire disorder (HSDD) or female sexual interest and arousal disorder (FSIAD). 15 Regardless of the disorder’s label, 15 , Reference Clayton, Goldfischer and Goldstein 16 if a woman suffers from prolonged loss of sexual desire that causes her distress and cannot be explained by problematic relationships, stressors, or medical conditions, then it is considered to be a disorder of reward processing for sex, and as such is hypothetically mediated by inefficient information processing in reward circuits.Reference Georgiadis and Kringelbach 1 – Reference Arnow, Millheiser and Garrett 6 Interest in and desire for sexual activity is the first phase of the human sexual response, followed by arousal, and then by orgasm (accompanied in men by ejaculation).Reference Georgiadis and Kringelbach 1 , Reference Pfaus 4 , Reference Stahl 17 , Reference Stahl 18 Disorders of orgasm and ejaculation have been recognized ever since the introduction of Prozac (fluoxetine) and the other selective serotonin reuptake inhibitors (SSRIs), which raise serotonin and commonly inhibit or delay orgasm/ejaculation.Reference Stahl 18 Disorders of arousal became well known with the introduction of Viagra (sildenafil citrate) and other nitric oxide synthase (NOS) inhibitors, which raise nitric oxide levels and enhance arousal, improving erections in men.Reference Stahl 18 Finally, disorders of interest in and desire for sex have also long been identified as a consequence of agents that enhance the release of serotonin (eg, SSRIs) or that block the release of dopamine (antipsychotics).Reference Stahl 3 , Reference Pfaus 4 , Reference Stahl 8 , Reference Stahl 18 However, until recently, primary disorders of interest in and desire for sex have not been well recognized.Reference Georgiadis and Kringelbach 1 – Reference Arnow, Millheiser and Garrett 6 Recent changes in diagnostic criteria for sexual disorders have arguably made it even more difficult to reach a primary diagnosis of loss of interest in and desire for sex. 15 Confusion exists because some diagnostic systems now merge disorders of interest and desire in women with disorders of arousal, while other diagnostic systems keep them separate. 15 , Reference Clayton, Goldfischer and Goldstein 16 Fortunately, as often occurs when a new therapeutic emerges, things are becoming clearer. It now seems that the primary disorder of loss of sexual interest and desire (not a disorder of arousal or orgasm) can be recognized and treated successfully when it occurs in premenopausal women.Reference Stahl, Sommer and Allers 7 , Reference Stahl 18 – Reference Simon, Kingsberg, Shumel, Hanes, Garcia and Sand 23 A microcircuit is one way to describe what happens at the level of a synapse between 2 neurons (see boxes in Figures 1–3). This is classically where neurotransmitters regulate brain functions and where drugs act. For example, each phase of the human sexual response appears to be regulated by different neurotransmitters operating within different microcircuits.Reference Georgiadis and Kringelbach 1 , Reference Pfaus 4 , Reference Stahl 17 , Reference Stahl 18 Interest and desire—sometimes called libido—are positively regulated not only by synaptic (microcircuit) dopamine (Figure 1A), but also by other microcircuits where norepinephrine (Figure 2A), testosterone, and estrogen act. Libido is also negatively modulated by microcircuits where prolactin and serotonin act (Figure 3A).Reference Georgiadis and Kringelbach 1 , Reference Pfaus 4 , Reference Stahl 17 Disorders of sexual interest and desire are hypothetically linked therefore to relative deficiencies in microcircuit dopamine (compare the microcircuits in Figures 1A and 1B) and norepinephrine (compare the microcircuits in Figures 2A and 2B) and a relative excess in microcircuit serotonin (compare the microcircuits in Figures 3A and 3B).Reference Georgiadis and Kringelbach 1 , Reference Pfaus 4 , Reference Stahl 17 Furthermore, prefrontal cortex (PFC) circuits utilizing glutamate may be overly active when sexual desire is low.Reference Stahl 2 HSDD may therefore be considered a maladaptation of the brain that arises from excessive excitatory signaling from the PFC to subcortical reward-related structures, which in turn leads to aberrant processing of information from rewarding events in both limbic and cortical areas.

Resource Center